share_log

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K:重大事件
美股sec公告 ·  05/23 08:35
Moomoo AI 已提取核心訊息
On May 21, 2024, Avenue Therapeutics, Inc. announced that it had received formal notice from The Nasdaq Stock Market LLC confirming the company's compliance with all necessary criteria for continued listing on The Nasdaq Capital Market. This includes meeting the minimum stockholders' equity requirement. The compliance notice effectively closes a previously disclosed listing issue. However, Avenue Therapeutics will be monitored by a Nasdaq Panel for one year until May 21, 2025. During this period, if the company fails to meet the Equity Rule, it will not be allowed to submit a compliance plan but will instead need to request a hearing before the Nasdaq Hearings Panel to address the deficiency.
On May 21, 2024, Avenue Therapeutics, Inc. announced that it had received formal notice from The Nasdaq Stock Market LLC confirming the company's compliance with all necessary criteria for continued listing on The Nasdaq Capital Market. This includes meeting the minimum stockholders' equity requirement. The compliance notice effectively closes a previously disclosed listing issue. However, Avenue Therapeutics will be monitored by a Nasdaq Panel for one year until May 21, 2025. During this period, if the company fails to meet the Equity Rule, it will not be allowed to submit a compliance plan but will instead need to request a hearing before the Nasdaq Hearings Panel to address the deficiency.
2024年5月21日,Avenue Therapeutics, Inc.宣佈已收到納斯達克股票市場有限責任公司的正式通知,確認該公司遵守了繼續在納斯達克資本市場上市的所有必要標準。這包括滿足最低股東權益要求。該合規通知實際上解決了先前披露的上市問題。但是,Avenue Therapeutics將由納斯達克小組進行爲期一年的監測,直到2025年5月21日。在此期間,如果公司未能滿足股權規則,則不允許提交合規計劃,而是需要要求納斯達克聽證會小組舉行聽證會以解決缺陷。
2024年5月21日,Avenue Therapeutics, Inc.宣佈已收到納斯達克股票市場有限責任公司的正式通知,確認該公司遵守了繼續在納斯達克資本市場上市的所有必要標準。這包括滿足最低股東權益要求。該合規通知實際上解決了先前披露的上市問題。但是,Avenue Therapeutics將由納斯達克小組進行爲期一年的監測,直到2025年5月21日。在此期間,如果公司未能滿足股權規則,則不允許提交合規計劃,而是需要要求納斯達克聽證會小組舉行聽證會以解決缺陷。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息